{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-039405","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.635420+00:00","generated_at":"2026-06-11T11:24:32.643247+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Roivant reports Q1 net loss of $327.8M, VTAMA revenue $16.7M; cash $1.45B","bullets":["Net loss $327.8M ($0.38/share) vs $353.8M ($0.48) YoY; non-GAAP net loss $211.5M.","Product revenue $16.7M from VTAMA (26% gross-to-net yield); ~200K prescriptions since launch.","Cash, equivalents, restricted cash $1.45B at June 30, down from $1.69B at March 31.","RVT-3101 shows improved efficacy at week 56 in UC Phase 2b; TAHOE Phase 2 in Crohn's initiated.","IMVT-1402 Phase 1 data expected Sep 2023 (SAD) and Oct/Nov 2023 (MAD); batoclimab MG data H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-039405","json":"https://secwatch.observer/filing/0001140361-23-039405.json","markdown":"https://secwatch.observer/filing/0001140361-23-039405.md","text":"https://secwatch.observer/filing/0001140361-23-039405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123039405/0001140361-23-039405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123039405/brhc20057388_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:24:32.643247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44637b9f76bb9ed64d4e775c6aeade3cb8722513","claim":"Roivant Sciences Ltd. reported financial results for the fiscal quarter ended June 30, 2023.","evidence_excerpt":"On August 14, 2023, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123039405/0001140361-23-039405-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ee0d503dbe8198fb8c18e592c614ee29416cc475","claim":"Roivant Sciences Ltd. reported the first quarter ended June 30, 2023 results: revenue $16.7M.","evidence_excerpt":"trial of IMVT-1402 remains on track for September 2023 (single-ascending dose) and October / November 2023 (multiple-ascending dose) • VTAMA® (tapinarof) net product revenue was $16.7M for the quarter ended June 30, 2023, with nearly 200,000 prescriptions written by approximately 11,500 unique prescribers since launch • VTAMA® gross-to-net yield was 26% for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123039405/0001140361-23-039405-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended June 30, 2023"},{"label":"Revenue","value":"$16.7M"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}